Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
Pfizer Inc. Chairman & CEO Albert Bourla acquired 20 Phantom Stock Units SSP on October 15, 2026, as a compensation-related award, at a reported $29.44 per unit. Each unit represents one phantom share of common stock, and his resulting position was 783,997 Phantom Stock Units SSP. The units are settled in cash following his separation from service.
Pfizer Inc. (PFE) reports that Chairman & CEO Albert Bourla acquired 71 Phantom Stock Units SSP on October 13, 2026, at a reported price of $28.37 per unit. The units were acquired pursuant to Pfizer Inc.’s Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock; the units are settled in cash following his separation from service and may be transferred into an alternative investment account at any time. His reported post-transaction balance was 783,981 Phantom Stock Units SSP.
Pfizer Inc. Chairman & CEO Albert Bourla acquired 21 Phantom Stock Units SSP on September 30, 2026, as an award. The transaction lists a price of $28.52 per share, and his reported direct position afterward was 783,888 units. Each unit represents one phantom share of common stock. The units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan and are settled in cash following his separation from service.
Pfizer Inc. director Mortimer J. Buckley acquired 1,308 Phantom Stock Units on September 25, 2026; the transaction lists a per-unit price of $28.67 and a resulting position of 28,040 units. The units represent deferred director's compensation, including dividend equivalents, and are settled in cash or common stock at his election following retirement from the Board of Directors.
Pfizer Inc director Joseph Echevarria acquired 1,613.185 Phantom Stock Units on September 25, 2026. The reported price was $28.67 per unit, and his reported balance after the acquisition was 169,739.319 units.
Each unit represents one phantom share of common stock. The units represent deferred director compensation, including dividend equivalents, and are settled in cash or common stock at the director’s election following his retirement from the Board of Directors.
Pfizer Inc. director Shantanu Narayen acquired 1,743.9830 Phantom Stock Units on September 25, 2026; the transaction lists $28.6700 per unit. The units represent deferred director's compensation, including dividend equivalents. Their terms provide for settlement in cash or common stock at his election following retirement from the Board. Narayen directly held 205,648.8230 Phantom Stock Units after the transaction.
Pfizer Inc. director James Quincey acquired 1,351.5870 Phantom Stock Units on September 25, 2026, at a reported price of $28.67 per unit. The units represent deferred director compensation, including dividend equivalents, and are settled in cash or common stock at his election following retirement from the Board. His reported resulting balance was 90,670.8470 Phantom Stock Units.
Pfizer director Cyrus Taraporevala was awarded 1,308 Phantom Stock Units on September 25, 2026, at a reported per-unit amount of $28.67, bringing his reported direct balance to 38,806 units. The award represents deferred director's compensation, including dividend equivalents, and will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
Pfizer Inc. director James C. Smith acquired 1,569.585 Phantom Stock Units on September 25, 2026, as deferred director's compensation, including dividend equivalents. Each unit represents one phantom share of common stock, and his reported position after the acquisition was 187,210.086 Phantom Stock Units. Following retirement from the Board of Directors, Smith may elect settlement in cash or common stock.
PFIZER INC (symbol: PFE) is the issuer of record for a Form 4 filing submitted to the SEC. BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC (PFE) reported that Chairman & CEO Albert Bourla received an award of 22 Phantom Stock Units SSP on September 15, 2026. Each unit represents one phantom share of common stock and was valued at $27.55 per unit, increasing his directly held phantom stock units to 783,985. The units were granted under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and will be settled in cash following his separation from service, with flexibility to transfer them into an alternative investment account at any time.